Two targeted drugs with chemoradiation for advanced head and neck cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial combines two drugs (sintilimab, an immunotherapy, and nimotuzumab, an EGFR-targeting therapy) before and during standard chemoradiation, to see if it improves outcomes for people with advanced head and neck cancer. The hope is that adding these targeted treatments will make the cancer more responsive to radiation and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer called squamous cell carcinoma that is stage III or IVB (locally advanced).
- Your tumor must test positive for a protein called EGFR.
- You have not had any prior treatment for this cancer (like chemotherapy or radiation).
- You are between 18 and 75 years old.
- You are generally able to perform daily activities (ECOG score of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) with radiation and chemotherapy for people with advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial tests a combination of two immunotherapy drugs (IBI110 and sintilimab) with chemotherapy before surgery for people with advanced head and neck cancer that can be removed surgically. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests whether combining two medicines – sintilimab (an immunotherapy) and cetuximab (a targeted therapy) – given before and after surgery can help treat advanced mouth or throat cancer. The study aims to see if this approach is safe and effective for patients whose cancer has not spread.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.